2013
A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria
Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria. Archives Of Pathology & Laboratory Medicine 2013, 138: 213-9. PMID: 24164555, DOI: 10.5858/arpa.2012-0617-oa.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinomaCohort StudiesConnecticutFemaleHospitals, UniversityHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMammary Glands, HumanMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm ProteinsPractice Guidelines as TopicReceptor, ErbB-2Retrospective StudiesSocieties, MedicalUnited StatesUnited States Food and Drug AdministrationToward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology 2013, 26: 1605-1612. PMID: 23765245, DOI: 10.1038/modpathol.2013.113.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaSerous carcinomaHER2 overexpressionEndometrial carcinomaMedical recordsImmunohistochemical scoreHER2 testingProtein expressionHER2 immunohistochemistrySignificant heterogeneityScoring systemMultiple tumor sectionsPure serous carcinomaHER2-positive casesHER2-positive tumorsScoring criteriaEndometrial carcinoma casesFDA criteriaPatients' medical recordsLarge academic centerHER2 FISH resultsHER2 protein overexpressionPromising therapeutic targetOverall concordance rateHER2 immunohistochemical scores
2011
BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance
Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C. BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance. Acta Cytologica 2011, 55: 570-575. PMID: 22156468, DOI: 10.1159/000333274.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiopsy, Fine-NeedleCarcinomaCarcinoma, PapillaryCell Transformation, NeoplasticDNA Mutational AnalysisFemaleHumansMaleMiddle AgedPractice Guidelines as TopicPredictive Value of TestsPrognosisProto-Oncogene Proteins B-rafRiskTerminology as TopicThyroid Cancer, PapillaryThyroid GlandThyroid NeoplasmsThyroid NoduleConceptsPapillary thyroid carcinomaBRAF mutation analysisBRAF mutationsUndetermined significanceFollicular lesionsUndetermined significance/follicular lesionFine needle aspiration cytology specimensAUS/FLUS categoryMutation analysisBRAF-positive casesIndeterminate thyroid FNAsAspiration cytology specimensRisk of malignancySurgical pathology outcomeFine-needle aspiration specimensBRAF mutation testingNegative predictive valueSurgical pathology reportsThyroid follicular lesionsPredictability of malignancyThyroid fine-needle aspiration specimensSurgical interventionFinal diagnosisPathology outcomesPathology reports